Your browser doesn't support javascript.
loading
A novel agent attenuates cardiotoxicity and improves antitumor activity of doxorubicin in breast cancer cells.
Zhang, Ying; Deng, Hongkuan; Zhou, Hefeng; Lu, Yucong; Shan, Luchen; Lee, Simon Ming-Yuen; Cui, Guozhen.
Afiliação
  • Zhang Y; Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
  • Deng H; Department of Pharmaceutical Engineering, School of Life Sciences, Shandong University of Technology, Zibo, China.
  • Zhou H; Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
  • Lu Y; Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
  • Shan L; Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, China.
  • Lee SM; State Key Laboratory of Quality Research in Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Macao, China.
  • Cui G; Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
J Cell Biochem ; 120(4): 5913-5922, 2019 04.
Article em En | MEDLINE | ID: mdl-30304553
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazinas / Doxorrubicina / Lactatos / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazinas / Doxorrubicina / Lactatos / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article